Search

Displaying results 6021 - 6030 of 10000 in total
  1. Drug

    Ethylmercurithiosalicylic acid

    go.drugbank.com/drugs/DB02731
    Experimental

    Ethylmercurithiosalicylic acid is a topical antiseptic used on skin and mucous membranes. It is also used as a preservative in pharmaceuticals.

  2. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    FDA approved on May 28, 2009.

  3. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocy...

  4. Drug

    Chlormerodrin

    go.drugbank.com/drugs/DB00534
    ApprovedWithdrawn

    Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of d...

  5. Drug

    Povidone K30

    go.drugbank.com/drugs/DB14478
    Approved

    A polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See povidone for full details.

  6. Drug

    Bremzalerbart

    go.drugbank.com/drugs/DB19417
    Investigational

    Bremzalerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen

  7. Drug

    Atisnolerbart

    go.drugbank.com/drugs/DB19418
    Investigational

    Atisnolerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen

  8. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  9. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  10. Drug

    LY-2599506

    go.drugbank.com/drugs/DB05970
    Investigational

    LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.

    Synonyms: (R)-2-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(PYRAZIN-2-YL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)PROPANAMIDE